Relay Therapeutics, Inc., was incorporated in Delaware on May 4, 2015. The company is a clinical-stage precision pharmaceutical company dedicated to transforming the drug discovery process, with an initial focus on enhancing small-molecule therapeutic discoveries in targeted oncology. The company is built on unparalleled insight into protein movement and the relationship between this dynamic behavior and protein function. The company's Dynamo platform integrates a range of advanced experimental and computational methods, allowing the company to apply its understanding of protein structure and movement to drug development. The company is developing its lead product candidates RLY-4008 and RLY-1971, and is developing drug candidates for the PI 3Kα Selective Mutant Program (RLY-PI 3K1047 Program) to treat patients with advanced solid tumors.